FDA and EU clear SonoCiné AWBUS is FDA-cleared as an adjunct to mammography and has European Union approvals for breast cancer screening in 27 countries, plus Health Canada approval. This regulatory footprint supports selling into multiple markets to clinics already performing breast imaging with standard ultrasound platforms.

Adjunctive value The system is designed as an add-on to existing ultrasound equipment rather than requiring dedicated rooms, enabling cost-effective adoption for clinics looking to enhance screening in women with dense breast tissue without significant capital expenditure.

Market traction Clinical validation includes a peer-reviewed large, multicenter prospective trial, which can be leveraged in sales pitches to radiology departments seeking evidence of improved screening performance and workflow efficiency.

Strategic partnerships Past collaborations with Philips and ongoing partnerships indicate a pathway for co-marketing and bundled imaging solutions, suggesting opportunities to approach ultrasound OEMs and distributors for integrated sales channels.

Growth potential With a revenue range of $1M-$10M and total funding of $14M, SonoCiné operates in a niche with room for expansion through 3D multiplanar reconstruction software and ongoing patent protection, presenting upsell potential to existing customers and expansion into additional markets.